OP0180 IMPACT OF RF AND ANTI-CITRULLINATED PROTEIN ANTIBODY SEROSTATUS ON 2-YEAR RETENTION OF ABATACEPT IN PATIENTS WITH RA

Background: Up to 50% of patients with RA discontinue DMARD treatment within 18 months. 1 However, up to 20% of patients who fail multiple treatments may have a good treatment response to another therapy. 1 Predictive biomarkers, such as RF and anti-citrullinated protein antibodies (ACPAs), may be useful to stratify patients with RA to the most appropriate treatment. 1 ASCORE ( A batacept S ub C utane O us in R outine Clinical Practic E ;...